Q-omics provides the consensus-scored ZC3H14 profile across patient tissues and cancer cell-line models. ZC3H14 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZC3H14 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZC3H14 protein abundance shows 32,457 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, HNSC, and GBM as cancer lineages where ZC3H14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3H14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3H14 survival associations across molecular data types. ZC3H14 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3H14 RNA expression–survival associations across cancer types. High ZC3H14 expression shows unfavorable associations in ACC, BLCA, LUSC and MESO, but favorable associations in BRCA and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZC3H14 RNA expression.
This table summarizes ZC3H14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZC3H14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3H14 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in HNSC, CHOL and BLCA. The HNSC box plot shows higher ZC3H14 RNA expression in tumor versus normal tissue (log2 FC = +0.568, t-test p < 0.001).
This table shows molecular features associated with ZC3H14 in patient tissues and cancer cell lines. In patient samples, ZC3H14 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3H14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
